Spots Global Cancer Trial Database for Early Dehiscence Markers in Ovarian Cancer Surgery
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Early Dehiscence Markers in Ovarian Cancer Surgery
Official Title: Procalcitonin and C-Reactive Protein as Early Anastomotic Dehiscence Markers in Ovarian Cancer Surgery
Study ID: NCT03131492
Interventions
Study Description
Brief Summary: EDMOCS trial pretends to evaluate if C-reactive protein (CRP) and procalcitonin (PCT) can predict intestinal anastomotic leaks before early discharge in advanced ovarian cancer surgery requiring intestinal resection. These markers have already been positively tested in colorectal cancer surgery, but not yet in ovarian surgery. Patients undergoing intestinal resection in ovarian cancer surgery will be included. C-reactive protein and PCT will be measured pre-operatively, and on the second, fourth and sixth postoperative day. Thirty-day readmissions, re-operations and mortality will be recorded.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Hospital Universitari de la Vall d'Hebron, Barcelona, , Spain
Contact Details
Name: Antonio Gil-Moreno, MD
Affiliation: Head of Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital
Role: STUDY_DIRECTOR
Name: Asunción Pérez-Benavente, MD
Affiliation: Head of Unit of Gynecology Oncology Department of Obstetrics and Gynecology
Role: STUDY_DIRECTOR
Name: José Luis Sánchez-Iglesias, MD
Affiliation: Department of Obstetrics and Gynecology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
